Navigation Links
China Cord Blood Corporation Announces Results of 2010 Annual General Meeting
Date:2/22/2011

HONG KONG, Feb. 22, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company"), the first and largest cord blood banking operator in China, today announced the results of its 2010 Annual General Meeting, which was held on February 18, 2011, in Hong Kong.

At the Annual General Meeting, shareholders

  • elected Albert Chen and Mark Chen to serve on the Board of Directors until the 2013 annual general meeting of the Company or until their respective successors are duly appointed and qualified;

  • ratified the appointment of KPMG as auditor of the Company for the financial year ending March 31, 2011, and authorized the directors to set the remuneration of the auditors; and

  • adopted the 2011 China Cord Blood Corporation Restricted Share Unit Scheme, or the "Incentive Plan," which has a mandate limit of granting rights to receive ordinary shares not exceeding 10.0% of the Company's issued and outstanding share capital, to directors, officers, employees and/or consultants of the Company and its subsidiaries and authorize directors to grant awards and allot and issue shares thereunder.

  • About China Cord Blood CorporationChina Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.  For more informat
    '/>"/>

    SOURCE China Cord Blood Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2

    Related biology technology :

    1. China Cord Blood Corporation to Announce Third Quarter Fiscal 2011 Financial Results
    2. China-Biotics to Report Fiscal Year 2011 Third Quarter Financial Results on February 9
    3. China-Biotics, Inc. Provides Preliminary FY2011Third Quarter Revenue
    4. Reportlinker Adds Industrial Biotechnology China News 1011
    5. Reportlinker Adds Financial Health of Biotechnology and Drugs Industry in India and China
    6. China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on February 18, 2011
    7. China-Biotics, Inc. to Hold 2010 Annual Meeting of Stockholders on March 9, 2011
    8. China Cord Blood Corporation Announces Completion of Warrant Exchange
    9. China-Biotics Announces Redemption of $25 million in Senior Convertible Notes
    10. China Cord Blood Corporation Announces Participation at the 29th Annual J.P. Morgan Healthcare Conference
    11. PRA International Expert to Speak at China Drug Safety Summit
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/20/2015)... Stent retriever thrombectomy, an endovascular technique ... brain reduced disability after stroke, according to a ... of the Society of Vascular and Interventional Neurology ... step forward that will change the way we ... Jovin, who is associate professor of Neurology and ...
    (Date:4/20/2015)... NC and Champaign, IL (PRWEB) April 20, 2015 ... today the establishment of its 12th clinical research site: ... PMG Research has assumed operation of the clinical research ... expanding PMG’s footprint outside the Southeast to a second ... within a 150 multi-specialty physician practice enhances PMG’s access ...
    (Date:4/20/2015)... FREMONT, Calif. , April 20, 2015 /PRNewswire/ ... biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic ... MBBS, MRCP, has joined the Company,s Board of ... management and board level experience, having built and ... clinical development, regulatory approval and into healthcare systems ...
    (Date:4/20/2015)... , April 20, 2015  Eli Lilly and ... data from several targeted cancer therapies, reflecting Lilly,s diverse ... (AACR) Annual Meeting 2015, held April 18-22 in ... Cancer Discoveries to Patients" is the theme of this ... Lilly,s commitment to broadening its portfolio of therapies that ...
    Breaking Biology Technology:SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6
    ... NOVATO, Calif., June 1 Raptor Pharmaceuticals Corp. ... today announced that it has dosed the first ... in collaboration with the University of California, ... delayed-release cysteamine bitartrate ("DR Cysteamine") capsules in nephropathic ...
    ... ... Mass Spectrometry-based biomarker discovery will be demonstrated at the 57th ASMS Conference on Mass ... , ... (PRWEB) June 1, 2009 -- Genedata , a leading provider of in silico ...
    ... from the first time point measured (1.5 hours) through ... Shire plc (LSE: SHP, Nasdaq: ... announced that the US Food and Drug Administration (FDA) ... its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE ...
    Cached Biology Technology:Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 2Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 3Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 4Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis 5Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 2Genedata Launches Expressionist with Expanded Mass Spectrometry Biomarker Discovery Capabilities 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 2FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 4FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 5FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 6FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 7
    (Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
    (Date:3/23/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet, ... March 30 th . The new ... York markets. Gino Pereira ... new ad campaign following the recent initial shipment of Wocket ...
    (Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
    Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
    ... Institutet have identified an important mechanism that regulates how ... cell. The study is published in the latest issue ... help us develop new drugs for things like neurological ... most organs of the body, old cells are continually ...
    ... To a tiny tadpole, life boils down to two basic ... The more a tadpole eats, the faster it grows big ... being active, which ups the odds of becoming someone else's ... activity levels in response to predation risk, but new research ...
    ... discovered how the brain creates a scent symphony from signals ... researchers found that nerve cells in the brain's olfactory bulb ... do not perceive complex scent mixtures as single objects, such ... cells, or neurons, detect the host of chemical compounds that ...
    Cached Biology News:New stem-cell findings can help the body to cure itself 2Time of day tempers tadpoles' response to predators 2Researchers show how brain decodes complex smells 2